Cancer in Angiogenesis

Unmet Need
In the United States alone, almost 8.5 million people suffer from peripheral artery disease (PAD). The market for PAD and Peripheral Vascular Disease (PVD) is expected to reach $378.53 million with a CAGR of 7.06% by 2024. Therapeutic angiogenesis are therapies aimed at growing new vessels into compromised tissue. Wound healing, PAD, and coronary artery disease (CAD) are improved by increasing circulation to the affected organs. Previous solutions utilize growth factors, which can be delivered at high concentrations to induce blood vessel budding and growth. Current treatments for PAD aim to manage symptoms and stop the progression of atherosclerosis. Medications are used to lower cholesterol in order to reduce the risk of heart attack and stroke.
 
 
Technology Overview
The proposed invention utilizes cancer cells to treat peripheral vascular disease, coronary artery disease and promote wound healing. A big concern in using cancer cells for therapeutic purposes proposes the idea that the introduction could lead to the spread of cancer. To combat this concern, the inventors have introduced thymidine kinase, a suicide gene, into the cancer cells. The inventor proposes two cancer cell lines in culture: The first is when the cancer cells are introduced into organs with severely compromised circulations, thus allowing blood vessels to grow. The patient is then treated with ganciclovir to kill the cancer cells and leaves the newly grown blood vessels behind. The second line is where the cancer cells bond to a matrix and is applied to the surface of a wound or compromised tissue. Cancer cells produce the proper concentrations of angiogenic growth factors to promote blood vessel growth. Once the matrix is removed, the host is treated with ganciclovir and the cancer cells are eliminated. Both cell lines offer a new method of using cancer cells to treat cardiovascular diseases.
 
Stage of Development
NA
 
Publications
NA
 

Category(s):